

Table 4.13
Cancer of the Female Breast (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	63	-	-	46	-	-
1970-1973 ^a	-	-	-	68	-	-	51	-	-
1975-1977 ^b	74.8	76.5	74.3	75.6	77.7	74.9	62.1	62.4	62.0
1978-1980 ^b	74.4	75.5	74.1	75.1	76.1	74.8	63.3	67.1	61.4
1981-1983 ^b	76.1	77.4	75.7	77.1	78.5	76.7	63.4	65.1	62.6
1984-1986 ^b	78.9	77.8	79.3	80.0	79.5	80.2	65.0	63.9	65.8
1987-1989 ^b	84.0	81.4	85.0	85.1	82.7	85.9	71.1	69.6	71.9
1990-1992 ^b	85.2	83.4	85.9	86.5	85.1	87.0	71.5	70.1	72.3
1993-1995 ^b	86.3	84.3	87.1	87.6	86.2	88.1	72.7	70.3	74.1
1996-1998 ^b	88.2	86.5	88.8	89.3	88.2	89.7	76.1	73.9	77.5
1999-2001 ^b	89.7	88.1	90.2	90.8	89.9	91.1	78.7	76.8	79.9
2002-2004 ^b	89.9	89.2	90.2	91.4	91.1	91.5	77.8	77.4	78.0
2005-2011 ^b	90.7 ^f	91.0 ^f	90.6 ^f	92.0 ^f	92.4 ^f	91.9 ^f	80.5 ^f	81.8 ^f	79.9 ^f
5-Year Period Survival (Percent) ^{cd}									
2011	89.6	89.7	89.7	90.8	90.9	90.8	80.4	81.0	80.3
Stage Distribution (%) 2005-2011 ^{ce}									
All Stages									
Number of cases	325,952	79,410	246,542	261,587	59,419	202,168	35,116	10,606	24,510
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	61	54	63	62	55	64	53	47	55
Regional	32	40	29	31	39	29	37	43	34
Distant	6	5	6	5	4	5	9	8	9
Unstaged	2	1	2	2	1	2	2	1	2
5-Year Relative Survival (Percent), 2005-2011 ^c									
Age at Diagnosis:									
Ages <45	88.2	-	-	89.6	-	-	78.6	-	-
Ages 45-54	90.5	-	-	91.7	-	-	81.2	-	-
Ages 55-64	90.0	-	-	91.1	-	-	80.6	-	-
Ages 65-74	90.9	-	-	91.9	-	-	81.6	-	-
Ages 75+	86.6	-	-	87.9	-	-	72.9	-	-
Ages <65	89.8	-	-	91.0	-	-	80.3	-	-
Ages 65+	88.9	-	-	90.0	-	-	78.0	-	-
Stage ^e :									
All Stages	89.4	89.5	89.4	90.6	90.8	90.6	79.6	80.3	79.3
Localized	98.6	96.7	99.1	99.2	97.1	99.7	94.3	93.6	94.6
Regional	84.9	86.6	84.2	86.3	88.2	85.5	74.9	76.2	74.2
Distant	25.9	35.6	23.1	27.1	38.6	24.3	17.1	23.7	14.4
Unstaged	51.7	74.2	46.8	49.5	75.1	44.6	50.6	65.1	46.1
<i>In Situ</i> ^j	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	100.0

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2012.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2012.

^d Period survival provides a 2011 estimate of survival by piecing together the most recent conditional survival estimates

from several cohorts. It is computed here using three year calendar blocks (2009-2011: 0-1 year survival), (2008-2010: 1-2 year survival), (2007-2009: 2-3 year survival), (2006-2008: 3-4 year survival), (2005-2007: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2005-2011 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

^j *In situ* cases are not included in the All Stages group.

- Statistic could not be calculated due to fewer than 25 cases during the time period.